Jaguar (JAGX) Q4 2025 Earnings Transcript
Image source: The Motley Fool.
Friday, April 10, 2026 at 7 a.m. ET
Jaguar Health (NASDAQ:JAGX) delivered a sequential revenue uptick following the out-license of Mytesi and Canalevia-CA1, which generated immediate non-dilutive cash inflows and shifted the company’s revenue mix. Significant losses persisted, with broader year-over-year declines in Mytesi prescription volume and escalating operational losses. Management reported meaningful parenteral support reductions in rare pediatric indications for crofelemer, advancing late-stage trials and asserting strategy alignment around licensing and business development. The company highlighted a sizable addressable rare-disease market and outlined explicit near-term regulatory and partnering milestones as primary value drivers.
Source Fool.com
